Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab long-term extension with randomized withdrawal in axial spondyloarthritis
NL-OMON47213Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in axial spondyloarthritis (axSpA) and non-radiographic axial spondyloarthritis (nr-axSpA) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Proportion of patients without flare during randomized withdrawal-retreatment period. Started Mar 2018; status: active, not recruiting.
02
Drugs
ixekizumab
03
Conditions
axial spondyloarthritis (axSpA)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NL-OMON47213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47213.